On September 24, 2026, Danish breast cancer research consortia highlighted the growing adoption of subcutaneous trastuzumab formulations to reduce infusion chair time in Copenhagen and Aarhus oncology units. Accessing authentic biologics like Herceptin (Trastuzumab) 660mg Injection remains a cornerstone of HER2-positive breast cancer management across Denmark.

At Critical Kare Pharma, we deliver batch-verified monoclonal antibodies with full Certificate of Analysis (COA) documentation, supporting Danish patients and clinics under EMA and Lægemiddelstyrelsen import frameworks.

HER2-Targeted Therapy in Danish Clinical Settings

• Subcutaneous 660mg Formulation: Enables a fixed-dose injection over 2–5 minutes, reducing hospital visit duration compared to IV infusion schedules.
• Biological Stability: Trastuzumab is heat-sensitive; exposure outside 2–8°C can reduce binding affinity and clinical efficacy.
• Import Documentation: Danish personal imports require a valid prescription, commercial invoice, COA, and batch traceability records for Lægemiddelstyrelsen review.

Explore delivery options on our Denmark country page or reach our Nordic support desk at support@Critical Kare Pharma.com.